XTRA:M12

Stock Analysis Report

Executive Summary

M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Europe.

Snowflake

Fundamentals

Flawless balance sheet with reasonable growth potential.

Share Price & News

How has M1 Kliniken's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

7.5%

M12

4.7%

DE Healthcare

4.1%

DE Market


1 Year Return

0.8%

M12

-21.0%

DE Healthcare

2.4%

DE Market

Return vs Industry: M12 exceeded the German Healthcare industry which returned -21% over the past year.

Return vs Market: M12 matched the German Market which returned 2.4% over the past year.


Shareholder returns

M12IndustryMarket
7 Day7.5%4.7%4.1%
30 Day17.3%-2.4%1.7%
90 Day-1.1%-5.3%3.7%
1 Year3.3%0.8%-19.6%-21.0%5.6%2.4%
3 Year69.6%57.3%-27.8%-30.4%19.2%8.9%
5 Yearn/a20.6%13.9%43.2%23.7%

Price Volatility Vs. Market

How volatile is M1 Kliniken's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is M1 Kliniken undervalued compared to its fair value and its price relative to the market?

23.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: M12 (€12.9) is trading below our estimate of fair value (€16.87)

Significantly Undervalued: M12 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: M12 is poor value based on its PE Ratio (30.4x) compared to the Healthcare industry average (25.8x).

PE vs Market: M12 is poor value based on its PE Ratio (30.4x) compared to the German market (19.5x).


Price to Earnings Growth Ratio

Low PEG Ratio: M12 is poor value based on its PEG Ratio (1.1x)


Price to Book Ratio

PB vs Industry: M12 is overvalued based on its PB Ratio (3.3x) compared to the DE Healthcare industry average (1.5x).


Next Steps

Future Growth

How is M1 Kliniken forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

27.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: M12's forecast earnings growth (27.4% per year) is above the savings rate (0.2%).

Earnings vs Market: M12's earnings (27.4% per year) are forecast to grow faster than the German market (12.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: M12's revenue (17.3% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: M12's revenue (17.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: M12's Return on Equity is forecast to be low in 3 years time (16%).


Next Steps

Past Performance

How has M1 Kliniken performed over the past 5 years?

-0.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: M12's earnings have declined by -0.7% per year over the past 5 years.

Accelerating Growth: M12's earnings growth over the past year (32.6%) exceeds its 5-year average (-0.7% per year).

Earnings vs Industry: M12 earnings growth over the past year (32.6%) exceeded the Healthcare industry 19.5%.


Return on Equity

High ROE: M12's Return on Equity (10.7%) is considered low.


Return on Assets

ROA vs Industry: M12 has a higher Return on Assets than the Healthcare industry average last year.


Return on Capital Employed

ROCE Improving: M12's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is M1 Kliniken's financial position?


Financial Position Analysis

Short Term Liabilities: M12's short term assets (€42.5M) exceeds its short term liabilities (€5.5M)

Long Term Liabilities: M12's short term assets (42.5M) exceeds its long term liabilities (11.4M)


Debt to Equity History and Analysis

Debt Level: M12's debt to equity ratio (0.2%) is considered satisfactory

Reducing Debt: M12's debt to equity ratio has reduced from 15.5% to 0.2% over the past 5 years.

Debt Coverage: M12's debt is well covered by operating cash flow (1148.9%).

Interest Coverage: M12 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: M12 has a high level of physical assets or inventory.

Debt Coverage by Assets: M12's debt is covered by short term assets (assets are 361.385470x debt).


Next Steps

Dividend

What is M1 Kliniken's current dividend yield, its reliability and sustainability?

2.33%

Current Dividend Yield


Dividend Yield vs Market

company2.3%marketbottom25%1.5%markettop25%3.8%industryaverage2.0%forecastin3Years2.6%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: M12's dividend (2.33%) is higher than the bottom 25% of dividend payers in the German market (1.45%).

High Dividend: M12's dividend (2.33%) is low compared to the top 25% of dividend payers in the German market (3.78%).

Stable Dividend: Whilst dividend payments have been stable, M12 has been paying a dividend for less than 10 years.

Growing Dividend: M12 has only been paying a dividend for 3 years, and since then payments have not increased.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (70.8%), M12's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: M12's dividends in 3 years are forecast to be covered by earnings (53.8% payout ratio).


Next Steps

Management

What is the CEO of M1 Kliniken's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average board tenure


CEO

Patrick Brenske 0

0yrs

Tenure

0

Mr. Patrick Brenske has been the Chief Executive Officer of MPH Mittelständische Pharma Holding AG since January 23, 2009 and has been its Member of Management Board since 2009. Mr. Brenske serves as Chief ...


Board Age and Tenure

2.3yrs

Average Tenure

Experienced Board: M12's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Walter von Horstig

    Member of Management Board

    • Tenure: 2yrs
  • Patrick Brenske

    CEO & Member of Management Board

    • Tenure: 0yrs

Board Members

  • Albert Wahl (59yo)

    Chairman of Supervisory Board

    • Tenure: 2.3yrs
  • Sabine Meck (64yo)

    Member of Supervisory Board

    • Tenure: 4.3yrs
  • Uwe Zimdars

    Deputy Chairman of Supervisory Board

    • Tenure: 2.3yrs

Company Information

M1 Kliniken AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: M1 Kliniken AG
  • Ticker: M12
  • Exchange: XTRA
  • Founded: 2007
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: €225.750m
  • Shares outstanding: 17.50m
  • Website: https://www.m1-kliniken.de

Number of Employees


Location

  • M1 Kliniken AG
  • Grünauer Strasse 5
  • Berlin
  • Berlin
  • 12557
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
M12DB (Deutsche Boerse AG)YesBearer SharesDEEURSep 2015
M12XTRA (XETRA Trading Platform)YesBearer SharesDEEURSep 2015

Biography

M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Europe. It develops and markets pharmaceutical, medical, and medical technology products for ae ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 22:01
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.